The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Moritz A.A.

Bekhterev National Medical Research Center for Psychiatry and Neurology

Terebova P.S.

Bekhterev National Medical Research Center for Psychiatry and Neurology

Ivanov M.V.

Bekhterev National Medical Research Center for Psychiatry and Neurology

The role of immuno-inflammatory factors in the development of negative symptoms in schizophrenia

Authors:

Moritz A.A., Terebova P.S., Ivanov M.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(11): 42‑48

DOI: 10.17116/jnevro202412411142

Read: 2320 times

Contact the author
Table of contents

THE ROLE OF IMMUNO-INFLAMMATORY FACTORS IN THE DEVELOPMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA
THE ROLE OF IMMUNO-INFLAMMATORY FACTORS IN THE DEVELOPMENT OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA

To cite this article:

Moritz AA, Terebova PS, Ivanov MV. The role of immuno-inflammatory factors in the development of negative symptoms in schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(11):42‑48. (In Russ.)
https://doi.org/10.17116/jnevro202412411142

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Modern concepts of sleep disturbances asso­ciated with mental diso­rders. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):7-12
Asso­ciation of cortisol levels with psychopathological features of depression and therapeutic response in female patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):45-54
Proinflammatory cyto­kines — as a marker of the effe­ctiveness of neuroprotection in children with peri­natal nervous system damage. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):62-66
The role of mono­cytes in the immu­nopathogenesis of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27
Prevalence of postpartum depression in the Russian Fede­ration: a systematic review and meta-analysis. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):74-87
Asso­ciations of gene­tic poly­morphisms in key inflammatory response genes with the risk of chro­nic apical periodontitis deve­lopment. Russian Journal of Stomatology. 2025;(2):52-56
Diagnostic stra­tegies for post-COVID syndrome. Russian Journal of Preventive Medi­cine. 2025;(6):126-130
Spectral analysis in meta­bolomics of skin neoplasms. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(3):277-283
Myokines — the cardiometabolic risk pote­ntial biomarkers. Russian Journal of Preventive Medi­cine. 2025;(7):119-126
Asso­ciations between sali­vary mela­tonin and periodontal disease: a systematic review and meta-analysis. Stomatology. 2025;(3):87-96
Abstract:

The literature review assessed the data obtained over the past 10 years on the relationship between inflammatory markers and the severity of negative symptoms in schizophrenia. A systematic search of the PubMed, Mendeley, and eLibrary databases was conducted in accordance with the PRISMA guidelines. Of the 407 publications found, 7 studies were selected by keywords that quantitatively assessed the relationship between the concentration of inflammatory markers and the severity of negative disorders in schizophrenia. Three publications reported statistically significant positive correlations between the level of tumor necrosis factor TNF-α and the scores of the negative subscale of the Positive and Negative Symptoms Scale (PANSS), two studies showed moderate correlations and weak correlations were reported in two publications. Two studies recorded reliable moderate and weak associations of negative symptoms with IL-1β, IL-6, IL-8, IL-10. A relationship was found between negative symptoms and the concentration of C-reactive protein, autoantibodies to neurotrophin S100b and myelin basic protein (MBP). In addition, immune-inflammatory indices of the neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and the Systemic Immune Inflammation Index (SII), which generally reflect the direction of the inflammatory response, were associated with the severity of negative disorders. The analyzed studies provided convincing data on the presence of reliable relationships between a number of cytokines and the severity of negative symptoms, which confirms previously published literature data on the pathogenetic role of neuroinflammation in the formation of negative symptoms.

Keywords:

schizophrenia
negative symptoms
neuroinflammation
cytokines
biomarkers
systematic review

Authors:

Moritz A.A.

Bekhterev National Medical Research Center for Psychiatry and Neurology

Terebova P.S.

Bekhterev National Medical Research Center for Psychiatry and Neurology

Ivanov M.V.

Bekhterev National Medical Research Center for Psychiatry and Neurology

Received:

19.06.2024

Accepted:

31.07.2024

Close metadata

References:

  1. Galderisi S, Mucci A, Bitter I, et al. Persistent negative symptoms in first episode patients with schizophrenia: results from the european first episode schizophrenia trial. Eur Neuropsychopharmacol. 2013;23(3):196-204.  https://doi.org/10.1016/j.euroneuro.2012.04.019
  2. Puspitosari WA, Soewadi S, Sumarni S. The Influence of Negative Symptoms on the Social Function of People with Schizophrenia in the Community. Berkala Kedokteran. 2018;14(2):123.  https://doi.org/10.20527/jbk.v14i2.5326
  3. Correll CU, Schooler NR. Negative symptoms in schizophrenia: a review and clinical guide for recognition, assessment, and treatment. Neuropsychiatr Dis Treat. 2020;16:519-534.  https://doi.org/10.2147/NDT.S225643
  4. Galderisi S, Rossi A, Rocca P, et al. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. World Psychiatry. 2014;13(3):275-287.  https://doi.org/10.1002/wps.20167
  5. Correll CU, Rubio JM, Inczedy-Farkas G, et al. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry. 2017;74(7):675-684.  https://doi.org/10.1001/jamapsychiatry.2017.0624
  6. Krogmann A, Peters L, von Hardenberg L, et al. Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities. CNS Spectr. 2019;24(S1):38-69.  https://doi.org/10.1017/S109285291900124X
  7. Kirkpatrick B, Fenton WS, Carpenter WT, et al. The NIMH-MATRICS Consensus Statement on Negative Symptoms. Schizophr Bull. 2006;32(2):214-219.  https://doi.org/10.1093/schbul/sbj053
  8. Kirkpatrick B, Strauss GP, Nguyen L, et al. The brief negative symptom scale: psychometric properties. Schizophr Bull. 2011;37(2):300-305.  https://doi.org/10.1093/schbul/sbq059
  9. Forbes C, Blanchard JJ, Bennett M, et al. Initial development and preliminary validation of a new negative symptom measure: the Clinical Assessment Interview for Negative Symptoms (CAINS). Schizophr Res. 2010;124(1-3):36-42.  https://doi.org/10.1016/j.schres.2010.08.039
  10. Llerena K, Park SG, McCarthy JM, et al. The Motivation and Pleasure Scale-Self-Report (MAP-SR): reliability and validity of a self-report measure of negative symptoms. Compr Psychiatry. 2013;54(5):568-574.  https://doi.org/10.1016/j.comppsych.2012.12.001
  11. Mosolov SN, Yaltonskaya PA. Primary and Secondary Negative Symptoms in Schizophrenia. Front Psychiatry. 2022;12:766692. https://doi.org/10.3389/fpsyt.2021.766692
  12. Klyushnik TP, Smulevich AB, Golimbet VYe, et al. The Creation of Clinical and Biological Concept of Schizophrenia: Participation of Chronic Inflammation and Genetic Predisposition in the Formation of Psychopathological Disorders. Psikhiatriya. 2022;20(2):6-13. (In Russ.). https://doi.org/10.30629/2618-6667-2022-20-2-6-13
  13. Miller BJ, Buckley P, Seabolt W, et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiat. 2011;70(7):663-671.  https://doi.org/10.1016/j.biopsych.2011.04.013
  14. Bloomfield PS, Selvaraj S, Veronese M, et al. Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [(11)C] PBR28 PET Brain Imaging Study. Am J Psychiatry. 2016;173(1):44-52.  https://doi.org/10.1176/appi.ajp.2015.14101358
  15. Réus GZ, Fries GR, Stertz L, et al. The role of inflammation and microglial activation in the pathophysiology of psychiatric disorders. Neuroscience. 2015;300:141-154.  https://doi.org/10.1016/j.neuroscience.2015.05.018
  16. Khalchitsky SE, Stanovaya VV, Yanushko MG, et al. Neuro-inflammatory theory of schizophrenia. Role of immunogenetic factors. Medline.ru. Rossijskij biomedicinskij zhurnal. 2024;25(17):257-318. (In Russ.). https://www.medline.ru/public/art/tom25/art17.html
  17. Goldsmith DR, Haroon E, Miller AH, et al. TNF-α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia. Schizophr Res. 2018;199:281-284.  https://doi.org/10.1016/j.schres.2018.02.048
  18. Goldsmith DR, Rapaport MH. Inflammation and negative symptoms of schizophrenia: implications for reward processing and motivational deficits. Front Psychiatry. 2020;11:46.  https://doi.org/10.3389/fpsyt.2020.00046
  19. Garcia-Rizo C, Fernandez-Egea E, Oliveira C, et al. Inflammatory markers in antipsychotic-naïve patients with nonaffective psychosis and deficit vs. nondeficit features. Psychiatry Res. 2012;198(2):212-215.  https://doi.org/10.1016/j.psychres.2011.08.014
  20. Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci. 2009;63(3):257-265.  https://doi.org/10.1111/j.1440-1819.2009.01945.x
  21. Upthegrove R, Manzanares-Teson N, Barnes NM. Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis. Schizophr Res. 2014;155(1-3):101-108.  https://doi.org/10.1016/j.schres.2014.03.005
  22. Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21(12):1696-1709. https://doi.org/10.1038/mp.2016.3
  23. Momtazmanesh S, Zare-Shahabadi A, Rezaei N. Cytokine alterations in schizophrenia: an updated review. Front Psychiatry. 2019;10:892.  https://doi.org/10.3389/fpsyt.2019.00892
  24. Moher D, Liberati A, Tetzlaff J, et al. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. https://doi.org/10.1136/bmj.b2535
  25. Krynicki CR, Dazzan P, Pariante CM, et al. Deconstructing depression and negative symptoms of schizophrenia; differential and longitudinal immune correlates, and response to minocycline treatment. Brain Behav Immun. 2021;91:498-504.  https://doi.org/10.1016/j.bbi.2020.10.026
  26. Klyushnik TP, Barkhatova AN, Sheshenin VS, et al. Specific features of immunological reactions in elderly and young patients with exacerbation of schizophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(2):53-59. (In Russ.). https://doi.org/10.17116/jnevro202112102153
  27. Šagud M, Madžarac Z, Nedic Erjavec G, et al. The Associations of Neutrophil–Lymphocyte, Platelet–Lymphocyte, Monocyte–Lymphocyte Ratios and Immune-Inflammation Index with Negative Symptoms in Patients with Schizophrenia. Biomolecules. 2023;13(2):297.  https://doi.org/10.3390/biom13020297
  28. Cyran A, Pawlak E, Piotrowski P, et al. The deficit subtype of schizophrenia is associated with a pro-inflammatory phenotype but not with altered levels of zonulin: Findings from a case-control study. Psychoneuroendocrinology. 2023;153:106109. https://doi.org/10.1016/j.psyneuen.2023.106109
  29. Enache D, Nikkheslat N, Fathalla D, et al. Peripheral immune markers and antipsychotic non-response in psychosis. Schizophr Res. 2021;230:1-8.  https://doi.org/10.1016/j.schres.2020.12.020
  30. Lin C, Chen K, Yu J, et al. Relationship between TNF-α levels and psychiatric symptoms in first-episode drug-naïve patients with schizophrenia before and after risperidone treatment and in chronic patients. BMC Psychiatry. 2021;21(1):561.  https://doi.org/10.1186/s12888-021-03569-5
  31. Boozalis T, Teixeira AL, Cho RY, et al. C-Reactive Protein Correlates with Negative Symptoms in Patients with Schizophrenia. Front Public Health. 2018;5:360.  https://doi.org/10.3389/fpubh.2017.00360
  32. Gorbunova AP, Rukavishnikov GV, Kasyanov ED, et al. The role of hematological coefficients of systemic inflammation in the diagnosis and risk assessment of affective disorders. V.M. Bekhterev Review of Psychiatry and Medical Psychology. 2024;58(1):47-55. (In Russ.). https://doi.org/10.31363/2313-7053-2024-794
  33. Carpenter WT, Heinrichs DW, Wagman AMI. Deficit and non-deficit forms of schizophrenia: The concept. American Journal of Psychiatry. 1988;145:578-583.  https://doi.org/10.1176/ajp.145.5.578
  34. Addington D, Addington J, Atkinson M. A Psychometric Comparison of the Calgary Depression Scale for Schizophrenia and the Hamilton Depression Rating Scale. Schizophr Res. 1996;19:205-212.  https://doi.org/10.1016/0920-9964(95)00070-4
  35. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia. Schizophrenia Bulletin. 1987;13(2):261-276.  https://doi.org/10.1093/schbul/13.2.261
  36. Müller N. Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations. Schizophr Bull. 2018;44(5):973-982.  https://doi.org/10.1093/schbul/sby024
  37. Watkins CC, Andrews SR. Clinical studies of neuroinflammatory mechanisms in schizophrenia. Schizophr Res. 2016;176(1):14-22.  https://doi.org/10.1016/j.schres.2015.07.018
  38. Kindler J, Lim CK, Weickert CS, et al. Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia. Mol Psychiatry. 2020;25(11):2860-2872. https://doi.org/10.1038/s41380-019-0401-9
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.